SLC5A2 and type 2 diabetes mellitus: Particularly in the light of HF, it is remarkable that the benefits mediated by SGLT‐2 inhibition seem rather preserved, also in populations without diabetes: results from the DAPA‐HF trial showed that dapagliflozin, added on top of standard of care in patients with and without T2DM with HF with reduced ejection fraction (HFrEF), was able to significantly reduce CV death and prevent worsening of HF overall and in both groups (DM and non‐DM), compared to placebo.81